News NICE rejects Shire pancreatic cancer drug Onivyde not eligible for Cancer Drugs Fund, says NICE.
News BMS' Opdivo approved in head and neck cancer BMS hopes survival data will give advantage over rival.
News NICE recommends Afinitor, Xalkori, as cancer drug review con... NICE has recommended two cancer drugs, as it continues its review of treatments in the old Cancer Drugs Fund.
News Expert questions survival benefit of cancer drugs Spending vast sums to extend life by weeks or months may be unethical, says doctor.
News BMS and Infinity look to boost Opdivo in lung cancer Companies look for combinations in lung cancer and other tumours.
News NICE rejects Amgen's Kyprolis in multiple myeloma NICE rejects drug despite efficacy and quality of life evidence.
News CMS aims for broader GLP-1 access via federal programmes CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
